Demand Affordable Access to GLP-1 Medications

Every year, 500,000 people in the U.S. lose their lives to conditions linked to obesity. That is more than 3,000 people every day, many of whom might have had a fighting chance with access to GLP-1 medications. These treatments can save lives, but access is being blocked at every turn:

• In 2025, many patients lost coverage altogether.

• Insurance is no safety net. People are denied, priced out, or stuck in endless red tape.

• Compounded GLP-1s are restricted to individual prescriptions under strict FDA rules.

• Out-of-pocket costs are unaffordable for most.

• Desperation is pushing patients toward unsafe, unregulated sources.

This is keeping people sick, and it is unacceptable.

That is why this step matters. Imagine if the 27,000+ people who already signed the petition, and the 400 who left powerful comments, all added their names here on Sway. Not just to show support, but to show intent to vote, to act, and to hold decision-makers accountable. That kind of collective record has the power to make policy makers pay attention.

This is not just another petition. It is proof that patients and allies are serious, organized, and ready to act.

How You Can Help:

• Add your name on Sway to show not only your support but your intent to vote for change.

• Share this campaign so policy makers can see the growing weight of our movement.

• Stay connected for updates on how voices like yours are being used to keep access at the center of the national conversation.

Every action makes our message harder to ignore. Together, we can turn signatures into real political power and make affordable access to GLP-1 medications a reality for everyone.

Pharmacy Benefit Managers (PBMs) were created to negotiate lower drug prices, but in reality they often do the opposite. Instead of saving patients money, PBMs exploit secret rebate deals with drug manufacturers that keep list prices high and block cheaper options from being covered.

For GLP-1 medications, PBMs are one of the biggest barriers standing between patients and treatment. They decide which versions of GLP-1s make it onto insurance formularies, often steering patients to the highest-rebate drugs rather than the most affordable or clinically appropriate ones. That means your health is dictated by hidden financial deals, not medical need.

We know this system is broken because of what companies like Cost Plus have shown us: when you take PBMs out of the equation, the price of medications drops dramatically. PBMs inflate costs and create layers of red tape that keep life-saving treatments out of reach.

Reforming PBMs is essential to making GLP-1s affordable and accessible. Reform would mean:

• Transparency: forcing PBMs to reveal the true flow of money and rebates.

• Fairer Coverage: ending the practice of blocking lower-cost or equally effective GLP-1 options.

• Lower Costs: cutting out unnecessary middlemen who profit while patients pay the price.

PBM reform is a vote for patients, not profiteers. If we want real affordable access to GLP-1s, we cannot get there without fixing the PBM system.

Why Patent Reform Matters for GLP-1 Access

Drug companies use patent evergreening to block competition and keep prices sky-high. Instead of protecting real innovation, they file dozens or even hundreds of minor patents, on delivery pens, dosing tweaks, or packaging, to extend monopolies far beyond what’s fair.

For GLP-1 medications, this means:

• No generics or biosimilars anytime soon, even though the science is well-established.

• Patients stuck paying $1,000+ per month while cheaper versions are kept off the market.

• Innovation stifled, because resources go into legal games instead of patient care.

Patent Reform would:

• End abusive evergreening practices that stretch exclusivity far beyond reason.

• Open the door for generics and biosimilars, driving costs down dramatically.

• Put patients over profits by making sure patents reward true medical breakthroughs, not paperwork tricks.

We should vote for leaders who are serious about Patent Reform. Without it, patients will keep paying inflated prices for decades. With it, we can finally unlock affordable access to GLP-1s.

Why We Need Drug Pricing Reform

The United States pays the highest prescription drug prices in the world. That is not because our medications are better. It is because the system allows drug companies to set prices without accountability. GLP-1 medications are one of the clearest examples.

• Patients are charged $1,000–$1,500 a month for medications that cost far less to produce.

• Other countries with stronger consumer protections pay only a fraction of what Americans do.

• Patients in the U.S. are left to pay out of pocket, go without, or risk dangerous unregulated sources.

What Drug Pricing Reform Means

• Give Medicare and Medicaid the power to negotiate lower prices, including for GLP-1s.

• Require transparency in how list prices are set and how rebates flow.

• Set reasonable limits on how much patients can be asked to pay out of pocket.

• Use international benchmarks so Americans stop paying ten times more for the same drugs.

Why This Matters for GLP-1 Access

• PBM reform and patent reform will help, but they cannot fix access alone.

• Without drug pricing reform, inflated list prices set by manufacturers will still block patients.

• Reform ensures GLP-1s are treated as a public health priority instead of a profit engine.

What We Are Voting For

• A system that values health over profit.

• Affordable GLP-1 access for every patient who needs it.

• An end to monopoly pricing, secret rebates, and financial barriers that keep people sick.